These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
387 related articles for article (PubMed ID: 36834917)
21. Nanomaterials to improve cancer immunotherapy based on ex vivo engineered T cells and NK cells. Han B; Song Y; Park J; Doh J J Control Release; 2022 Mar; 343():379-391. PubMed ID: 35124129 [TBL] [Abstract][Full Text] [Related]
22. Cancer immunotherapies revisited: state of the art of conventional treatments and next-generation nanomedicines. García-Fernández C; Saz A; Fornaguera C; Borrós S Cancer Gene Ther; 2021 Sep; 28(9):935-946. PubMed ID: 33837365 [TBL] [Abstract][Full Text] [Related]
23. Circulating biomarkers predictive of tumor response to cancer immunotherapy. Lee EY; Kulkarni RP Expert Rev Mol Diagn; 2019 Oct; 19(10):895-904. PubMed ID: 31469965 [No Abstract] [Full Text] [Related]
24. Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers. Spiliopoulou P; Vornicova O; Genta S; Spreafico A Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674809 [TBL] [Abstract][Full Text] [Related]
25. Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatment. Masaoutis C; Kokkali S; Theocharis S Expert Opin Investig Drugs; 2021 May; 30(5):555-569. PubMed ID: 33650931 [TBL] [Abstract][Full Text] [Related]
26. Immunotherapy in Melanoma: Highlights for the General Practitioner. Ben Aïssa A Praxis (Bern 1994); 2023; 112(3):135-142. PubMed ID: 36855885 [No Abstract] [Full Text] [Related]
27. [Principles of adoptive cell therapy based on "Tumor Infiltrating Lymphocytes"]. Martins F; Orcurto A; Michielin O; Coukos G Rev Med Suisse; 2016 May; 12(519):989-93. PubMed ID: 27424426 [TBL] [Abstract][Full Text] [Related]
28. T cell receptor therapy against melanoma-Immunotherapy for the future? Winge-Main AK; Wälchli S; Inderberg EM Scand J Immunol; 2020 Oct; 92(4):e12927. PubMed ID: 32640053 [TBL] [Abstract][Full Text] [Related]
29. Current trends in the treatment of malignant melanoma. Valko-Rokytovska M; Bruchata K; Simkova J; Milkovicova M; Kostecka Z Neoplasma; 2016; 63(3):333-41. PubMed ID: 26925781 [TBL] [Abstract][Full Text] [Related]
35. Immunotherapy for melanoma. Kim CJ; Dessureault S; Gabrilovich D; Reintgen DS; Slingluff CL Cancer Control; 2002; 9(1):22-30. PubMed ID: 11907463 [TBL] [Abstract][Full Text] [Related]
36. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift? Madden DL Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148 [TBL] [Abstract][Full Text] [Related]
37. Engineered nano-immunopotentiators efficiently promote cancer immunotherapy for inhibiting and preventing lung metastasis of melanoma. Luo L; Iqbal MZ; Liu C; Xing J; Akakuru OU; Fang Q; Li Z; Dai Y; Li A; Guan Y; Wu A Biomaterials; 2019 Dec; 223():119464. PubMed ID: 31525691 [TBL] [Abstract][Full Text] [Related]
38. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors. Medikonda R; Pant A; Lim M Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382 [TBL] [Abstract][Full Text] [Related]
39. [Cancer immunotherapy by immuno-checkpoint blockade]. Kawakami Y Rinsho Ketsueki; 2015 Oct; 56(10):2186-94. PubMed ID: 26458459 [TBL] [Abstract][Full Text] [Related]
40. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy). Ascierto PA; Agarwala SS; Blank C; Caracò C; Carvajal RD; Ernstoff MS; Ferrone S; Fox BA; Gajewski TF; Garbe C; Grob JJ; Hamid O; Krogsgaard M; Lo RS; Lund AW; Madonna G; Michielin O; Neyns B; Osman I; Peters S; Poulikakos PI; Quezada SA; Reinfeld B; Zitvogel L; Puzanov I; Thurin M J Transl Med; 2022 Sep; 20(1):391. PubMed ID: 36058945 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]